Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
X. Li
Observed names:
Xinmin Li,
Xue'er Li,
Xuejuan Li
Institution:
Henan University of Chinese Medicine
Observed institutions:
Henan University of Chinese Medicine,
Capital Medical University,
Beijing Tian Tan Hospital,
Jiangmen Central Hospital,
Jiangsu Hengrui Medicine (China),
Shenzhen Children's Hospital,
First Affiliated Hospital of Zhengzhou University,
Liaoning Cancer Hospital & Institute
show all 8
ORCID:
0000-0002-6301-3736
Observed ORCID:
0000-0002-6301-3736
OpenAlex ID:
A5044546691
Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial
2020
·
M. Shi
, A. Gu
, et al.
·
Annals of Oncology
·
82
VP9-2021: ORIENT-31: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy
2021
·
S. Lu
, L. Wu
, et al.
·
Annals of Oncology
·
39
PDF
653O Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) in patients with KRAS p.G12C mutated solid tumors
2023
·
J. Wang
, J. Zhao
, et al.
·
Annals of Oncology
·
31
PDF
96O Camrelizumab or placebo plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-sq): A randomized, double-blind, multicenter, phase III trial
2021
·
C. Zhou
, S. Ren
, et al.
·
Journal of Thoracic Oncology
·
30
PDF
Efficacy and safety of surufatinib in patients with well-differentiated advanced extrapancreatic neuroendocrine tumors (NETs): Results from the randomized phase III study (SANET-ep)
2019
·
J. Xu
, L. Shen
, et al.
·
Annals of Oncology
·
21
PDF
1300P A phase Ib/II trial of AK104 (PD-1/CTLA-4 bispecific antibody) in combination with anlotinib in advanced NSCLC
2021
·
L. Wu
, B. Chen
, et al.
·
Annals of Oncology
·
20
550O Safety and efficacy of D-1553 in combination with cetuximab in KRAS G12C mutated colorectal cancer (CRC): A phase II study
2023
·
R-H. Xu
, Y. Xu
, et al.
·
Annals of Oncology
·
19
PDF
Clinical and dermoscopic features of common warts
2016
·
X. Li
, J. Yu
, et al.
·
Journal of the European Academy of Dermatology and Venereology
·
18
Efficacy of different analgesic strategies combined with conventional physiotherapy program for treating chronic shoulder pain: a systematic review and network meta-analysis
2024
·
Fangjie Yang
, Xinmin Li
, et al.
·
Journal of Orthopaedic Surgery and Research
·
16
PDF
Efficacy and safety of mind-body exercise for patients with axial spondyloarthritis: a systematic review and meta-analysis
2024
·
Jing Wang
, Xinmin Li
, et al.
·
Journal of Orthopaedic Surgery and Research
·
13
PDF
MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC
2021
·
J. Wang
, Z. Wang
, et al.
·
Journal of Thoracic Oncology
·
13
P77.03 A Phase II Study of KN046 (Bispecific Anti-PD-L1/CTLA-4) in Patients (pts) with Metastatic Non-Small Cell Lung Cancer (NSCLC)
2021
·
C. Zhou
, A. Xiong
, et al.
·
Journal of Thoracic Oncology
·
13
PDF
1263P Tislelizumab + chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous NSCLC
2020
·
S. Lu
, Y. Yu
, et al.
·
Annals of Oncology
·
13
62P First-line (1L) camrelizumab plus chemotherapy (chemo) for advanced squamous non-small cell lung cancer (sqNSCLC): 4-yr update from the phase III CameL-sq trial
2024
·
C. Zhou
, S. Ren
, et al.
·
ESMO Open
·
12
2MO Final OS results and subgroup analysis of savolitinib in patients with MET exon 14 skipping mutations (METex14+) NSCLC
2022
·
S. Lu
, J. Fang
, et al.
·
Annals of Oncology
·
11
1445P CS1001, an anti-PD-L1 antibody, combined with standard of care (SOC) chemotherapy for first line (1L) advanced GC/GEJ and ESCC: Preliminary results from 2 phase Ib cohorts of CS1001-101 study
2020
·
L. Shen
, J. Li
, et al.
·
Annals of Oncology
·
11
JCSE01.09 A Phase II Umbrella Study of Camrelizumab in Different PD-L1 Expression Cohorts in Pre-Treated Advanced/Metastatic Non-Small Cell Lung Cancer
2019
·
Y. Wu
, C. Huang
, et al.
·
Journal of Thoracic Oncology
·
11
1278P SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, as first-line therapy for PD-L1+ advanced/metastatic NSCLC: Data from a clinical expansion cohort of a phase I study
2021
·
J. Feng
, J. Chen
, et al.
·
Annals of Oncology
·
9
PDF
1459P Preliminary efficacy and safety of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer who previously treated with immune checkpoint inhibitor(s)
2023
·
C. Zhou
, A. Xiong
, et al.
·
Annals of Oncology
·
8
PDF
3MO First-line camrelizumab plus carboplatin and paclitaxel for advanced squamous non-small cell lung cancer: Updated overall survival results from the phase III CameL-sq trial
2022
·
C. Zhou
, Y. Cheng
, et al.
·
Annals of Oncology
·
8
P1.01-61 A Phase II Umbrella Study of Camrelizumab in Different PD-L1 Expression Cohorts in Pre-Treated Advanced/Metastatic Non-Small Cell Lung Cancer
2019
·
Y. Wu
, C. Huang
, et al.
·
Journal of Thoracic Oncology
·
8
PDF
196MO Anlotinib plus etoposide/carboplatin (EC) versus placebo plus EC in first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): A randomized, double-blind, parallel controlled, phase III trial (ETER 701)
2024
·
Y. Cheng
, R. Yang
, et al.
·
ESMO Open
·
7
RETRACTED: ORIENT-3: A randomized, open-label, phase III study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small cell lung cancer (sqNSCLC)
2020
·
Y. Shi
, L. Wu
, et al.
·
Annals of Oncology
·
7
Characterizing kinase intergenic-breakpoint rearrangements in a large-scale lung cancer population and real-world clinical outcomes
2022
·
Y. Yao
, Z. Yu
, et al.
·
ESMO Open
·
6
Therapeutic efficacy and pharmacological mechanism of Yindan Xinnaotong soft capsule on acute ischemic stroke: a meta-analysis and network pharmacology analysis
2023
·
Fangjie Yang
, Xinmin Li
, et al.
·
Metabolic Brain Disease
·
5
Show more works
View as search
Works count:
61
Citation count:
486
H-index:
13
I10-index:
17
Year
Topic
Type